Novel Catheter for Treatment of Ventricular Tachycardia

治疗室性心动过速的新型导管

• 批准号: 6665293
• 负责人: MICHAEL G CURLEY
• 金额: $ 53.39万
• 依托单位: THERMEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-09-29 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6665293
• 关键词: biomedical equipment development; electrodes; heart catheterization; laser therapy; lasers; method development; myocardium; radiowave radiation; saline; swine; tachycardia; temperature; thermometry

DESCRIPTION (provided by applicant): Sudden cardiac death kills 300,000 people in the United States yearly. More than half of these deaths are caused by arrhythmias including ventricular tachycardia. Radiofrequency ablation, which successfully treats supraventricular tachycardia, is not successful at treating ventricular tachycardia because conventional RF ablation catheters cannot treat a large enough volume of myocardium. In Phase 1 of this project, we have demonstrated the feasibility of saline-enhanced ablation. We will have used infusion of warm saline through the myocardium (simultaneous with the application of radiofrequency or laser heating energy) to increase the tissue thermal transport by a factor of 20 or more. We have shown that this method can increase the volume of thermal lesions in myocardium by a factor of 12. These lesions are capable of treating the full thickness of the myocardium, and therefore show promise toward treatment of ventricular tachycardia. We will continue the development of this system during this Phase 2 project. Based on the Phase 1 results we will continue our development using saline enhanced radiofrequency ablations. We will develop a steerable catheter that will have a porous radiofrequency electrode at the tip, which will be inserted into the myocardium. The catheter will have a central lumen with an RF heater to heat the saline before injecting it into the myocardiurn. We will qualify this prototype catheter and system in preclinical studies of ventricular tachycardia in animal models at the Mayo Clinic and the Brigham and Women's Hospital.

描述（由申请人提供）：心脏性猝死每年在美国造成30万人死亡。这些死亡中有一半以上是由心律失常引起的，包括室性心动过速。成功治疗室上性心动过速的射频消融术在治疗室性心动过速方面并不成功，因为传统的射频消融导管无法治疗足够大体积的心肌。在该项目的第1阶段，我们已经证明了盐水增强消融的可行性。我们将通过心肌灌注温盐水（同时应用射频或激光加热能量），以将组织热传输增加20倍或更多。我们已经表明，这种方法可以增加心肌热损伤的体积的一个因素的12。这些病变能够治疗整个心肌层，因此显示出治疗室性心动过速的前景。我们将在第二阶段项目中继续开发该系统。根据第1阶段的结果，我们将继续使用生理盐水增强射频消融进行开发。我们将开发一种可操纵导管，其尖端将有一个多孔射频电极，将插入心肌。导管将有一个带有射频加热器的中心腔，用于在将生理盐水注入心肌之前加热生理盐水。我们将在马约诊所和布莱根妇女医院的动物模型中对该原型导管和系统进行室性心动过速临床前研究。